One Carbon Therapeutics has been selected to present the MTHFD1/2 project to the International Board of MATWIN on May 10-11 th

by admin
maj 2, 2023

We are excited to discuss our science and program with major pharma leaders.

Rekommenderade artiklar

Dr Eva Ehrnrooth, MD PhD to join One-carbon Therapeutics AB management team as interim CMO

Dr Eva Ehrnrooth (MD PhD) brings + 20 years of

One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe

One-carbon therapeutics AB is discussing the ODIN trial with several

Our Founder Prof Thomas Helleday wins the Anders Jahre’s price in Medicine

Read the article here.

Menu bar